Corbus Pharmaceuticals has surged 36% pre-market after reporting that its Phase 1a study showed CRB-913 was safe and well-tolerated with no serious adverse events. The oral CB1 inverse agonist also reduced food-related thoughts and cravings. Corbus has begun its Phase 1b dose-finding trial, expected to finish in summer 2026.